Global Pulmonary Drug Delivery Systems Market 2015-2019

About Pulmonary Drug Delivery Systems
Pulmonary delivery of drugs leads to the deposition of drugs in the lungs and subsequent local or systemic therapeutic activity. The pulmonary route of administration for the non-invasive delivery of drugs is mostly preferred because of the large surface area for absorption, high blood circulation, and high permeability rate. Pulmonary drug delivery offers various advantages over peroral routes, such as bypass of hepatic first-pass metabolism, quick onset of action, and low enzymatic activity. Pulmonary delivery of drugs can be achieved by intranasal administration or oral inhalative administration, the latter being more effective. Oral inhalative administration includes intratracheal inhalation and intratracheal instillation. Oral inhalation delivers the aerosolized drug using devices such as MDIs (or pMDIs), PDIs, and nebulizers. Drugs administered by this route are deposited in the respiratory tract via inertial impaction, gravitational sedimentation, and diffusion. The effective delivery of drugs via the pulmonary route requires an optimized combination of drug, its formulation, and device.
TechNavio's analysts forecast the Global Pulmonary Drug Delivery Systems market to grow at a CAGR of 8.90 percent over the period 2014-2019.

Covered in this Report
This report covers the present scenario and the growth prospects of the Global Pulmonary Drug Delivery Systems market for the period 2015-2019. To calculate the market size, the report considers the revenue from the sales of various pulmonary drug delivery systems intended for oral inhalation including:
• MDIs (or pMDIs)
• DPIs
• Nebulizers
TechNavio's report, the Global Pulmonary Drug Delivery Systems Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Pulmonary Drug Delivery Systems market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions
• Americas
• APAC
• EMEA  
     
Key Vendors
• AstraZeneca
• Boehringer Ingelheim
• GlaxoSmithKline
• Novartis
• Philips Healthcare

Other Prominent Vendors
• 3M Health Care
• Actelion Pharmaceuticals
• Aerogen
• Airon
• Allied Healthcare Products
• Briggs Healthcare
• Carefusion
• Clement Clarke International
• DeVilbiss Healthcare
• Drive Medical Design and Manufacturing
• GF Health Products
• Heyer Medical
• OMRON
• PARI Medical Holding
• Salter Labs
• Teleflex

Market Driver
• Increase in Prevalence and Incidence of Respiratory Diseases
• For a full, detailed list, view our report

Market Challenge
• Intense Market Competition
• For a full, detailed list, view our report

Market Trend
• Increase in Online Marketing Services
• For a full, detailed list, view our report

Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?